FDA Rejects Rocket’s Gene Therapy, Cites Need for Additional CMC Info

[cafead]

via Rocket Pharmaceuticals announced Friday that the FDA rejected its rare disease gene therapy Kresladi (marnetegragene autotemcel) in a Complete Response Letter requesting “limited additional” chemistry, manufacturing and controls information to complete the regulator’s review

article source